Pacific Century Premium Developments Limited (PCPDF)

CTI BioPharma Balance Sheet

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	707	659	865	596	1,516	1,202
Short-Term Investments	-	-	-	90	1,942	-
Trading Asset Securities	-	-	-	-	-	2
Cash & Short-Term Investments	707	659	865	686	3,458	1,204
Cash Growth	29.96%	-23.82%	26.09%	-80.16%	187.21%	-12.94%
Accounts Receivable	40	100	101	63	39	34
Other Receivables	-	15	11	19	20	21
Receivables	40	115	112	82	59	55
Inventory	3,781	3,572	3,341	269	277	296
Prepaid Expenses	116	112	91	115	437	427
Restricted Cash	68	71	43	153	119	113
Other Current Assets	8	8	9	506	504	504
Total Current Assets	4,720	4,537	4,461	1,811	4,854	2,599
Property, Plant & Equipment	2,353	2,228	2,374	2,563	3,122	3,367
Long-Term Investments	1	1	1	1	8	1
Goodwill	3	3	4	4	4	5
Long-Term Deferred Tax Assets	21	34	-	-	-	-
Other Long-Term Assets	4,038	4,064	4,185	6,911	7,058	7,021
Total Assets	11,136	10,867	11,025	11,290	15,046	12,993
Accounts Payable	14	53	51	20	15	14
Accrued Expenses	255	303	321	342	473	713
Short-Term Debt	8,640	805	497	615	2,417	807
Current Portion of Long-Term Debt	-	30	34	9	10	11
Current Portion of Leases	23	24	25	22	25	27
Current Income Taxes Payable	41	25	14	8	11	11
Current Unearned Revenue	163	300	230	144	78	90
Other Current Liabilities	-	-	-	335	334	330
Total Current Liabilities	9,136	1,540	1,172	1,495	3,363	2,003
Long-Term Debt	1,674	9,006	8,910	8,350	8,880	7,385
Long-Term Leases	21	24	13	17	34	7
Long-Term Unearned Revenue	1	12	30	-	16	34
Long-Term Deferred Tax Liabilities	37	36	33	30	28	39
Other Long-Term Liabilities	186	183	185	185	181	178
Total Liabilities	11,055	10,801	10,343	10,077	12,502	9,646
Common Stock	3,802	3,802	3,802	3,802	3,802	3,438
Retained Earnings	-	-1,270	-1,040	-574	24	849
Comprehensive Income & Other	-3,854	-2,599	-2,213	-2,148	-1,415	-1,073
Total Common Equity	-52	-67	549	1,080	2,411	3,214
Minority Interest	133	133	133	133	133	133
Shareholders' Equity	81	66	682	1,213	2,544	3,347
Total Liabilities & Equity	11,136	10,867	11,025	11,290	15,046	12,993
Total Debt	10,358	9,889	9,479	9,013	11,366	8,237
Net Cash (Debt)	-9,651	-9,230	-8,614	-8,327	-7,908	-7,033
Net Cash Per Share	-4.73	-4.53	-4.23	-4.09	-4.07	-4.43
Filing Date Shares Outstanding	2,036	2,038	2,038	2,038	2,038	1,587
Total Common Shares Outstanding	2,036	2,038	2,038	2,038	2,038	1,587
Working Capital	-4,416	2,997	3,289	316	1,491	596
Book Value Per Share	-0.03	-0.03	0.27	0.53	1.18	2.02
Tangible Book Value	-55	-70	545	1,076	2,407	3,209
Tangible Book Value Per Share	-0.03	-0.03	0.27	0.53	1.18	2.02
Land	-	231	237	239	256	276
Buildings	-	2,200	2,230	2,336	2,549	2,558
Machinery	-	620	599	607	663	579
Construction In Progress	-	27	54	13	155	340

Source: S&P Global Market Intelligence. Standard template. Financial Sources.